A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: Ineffectiveness in head-and-neck dermatitis

Ida Vittrup, Niels Steen Krogh, Henrik Hedegaard Pliess Larsen, Jesper Elberling, Lone Skov, Kristina Sophie Ibler, Gregor B.E. Jemec, Charlotte G. Mortz, Rasmus Overgaard Bach, Carsten Bindslev-Jensen, Maiken Glud Dalager, Alexander Egeberg, Tove Agner, Mette Deleuran, Christian Vestergaard, Jacob Pontoppidan Thyssen*


Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

12 Downloads (Pure)


Background: Evaluation of effectiveness and safety of new systemic treatments for atopic dermatitis (AD) after approval is important. There are few published data exceeding 52-week therapy with dupilumab. Objectives: To examine the safety, effectiveness and drug survival of dupilumab in a Danish nationwide cohort with moderate-to-severe AD up to 104 weeks exposure. Methods: We included 347 adult patients with AD who were treated with dupilumab and registered in the SCRATCH registry during 2017–2022. Results: At all visits, we observed improvement in AD severity measured by Eczema Area and Severity Index (EASI) [median (IQR)]. EASI score at baseline was 18.0 (10.6–25.2), at week 4: 6.5 (3.5–11.6), at week 16: 3.7 (1.2–6.2), at week 52: 2.0 (0.8–3.6), at week 104: 1.7 (0.8–3.8). While drug survival was high (week 52: 90%; week 104: 86%), AD in the head-and-neck area remained present in most patients at high levels; proportion with head-and-neck AD at baseline was 76% and 68% at week 104. 35% of patients reported any AE. Conjunctivitis was the most frequent (25% of all patients) and median time to first registration of conjunctivitis was 201 days. Conclusions: While 2-year drug survival was 86%, dupilumab was unable to effectively treat AD in the head-and-neck area, and conjunctivitis was found in 25% of patients.

TidsskriftJournal of The European Academy of Dermatology and Venereology
Udgave nummer5
Sider (fra-til)1046-1055
StatusUdgivet - maj 2023

Bibliografisk note

Funding Information:
The SCRATCH register has been financially supported by two independent research grants from Sanofi‐Genzyme and one grant from Pfizer. The supports were not involved in the research questions, design, analysis or interpretation of data.


Dyk ned i forskningsemnerne om 'A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: Ineffectiveness in head-and-neck dermatitis'. Sammen danner de et unikt fingeraftryk.